Reuters logo
in 4 months
BRIEF-Ocera to announce additional results from its phase 2b STOP-HE study of IV OCR-002
March 8, 2017 / 1:35 PM / in 4 months

BRIEF-Ocera to announce additional results from its phase 2b STOP-HE study of IV OCR-002

1 Min Read

March 8 (Reuters) - Ocera Therapeutics Inc

* Ocera to announce additional results from its phase 2b STOP-HE study of IV OCR-002 in patients with hepatic encephalopathy

* Ocera Therapeutics Inc - IV OCR-002 statistically significantly normalized ammonia faster than standard of care

* Ocera Therapeutics Inc - ammonia reduction statistically significantly correlated with clinical improvement in he symptoms

* Ocera Therapeutics Inc - Ocera plans to meet with FDA in Q3 2017 to inform development paths forward for IV OCR-002 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below